1. Proton therapy for pediatric and adolescent esthesioneuroblastoma.

    Pediatric Blood & Cancer 62(9):1523 (2015) PMID 25820437

    Esthesioneuroblastoma (EN) of the paranasal sinus comprises less than 3% of tumors of in pediatric and adolescent patients [1]. The collective adult literature indicates a critical role for radiotherapy in attaining cure [2], yet pediatric outcome data is limited. Radiation in pediatric patients...
  2. Case records of the Massachusetts General Hospital. Case 12-2015. A newborn boy with respiratory distress, lethargy, and hypernatremia.

    New England Journal of Medicine 372(16):1550 (2015) PMID 25875261

  3. Genetic Analysis of Giant Cell Tumors of the Axial/Appendicular and Maxillofacial Skeleton

    Journal of the American College of Surgeons 219(3):S70 (2014)

  4. Clinical Outcomes and Late Endocrine, Neurocognitive, and Visual Profiles of Proton Radiation for Pediatric Low-Grade Gliomas

    International Journal of Radiation Oncology*Bio... 89(5):1060 (2014)

    Purpose/Objective(s) Primary low-grade gliomas are common brain tumors of childhood, many of which require radiation therapy (RT) as definitive treatment. Increased conformality of RT could decrease the incidence and severity of late effects. We report our experience with 32 ...
  5. Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas.

    International Journal of Radiation Oncology*Bio... 89(5):1060 (2014) PMID 25035209

    Primary low-grade gliomas are common brain tumors of childhood, many of which require radiation therapy (RT) as definitive treatment. Increased conformality of RT could decrease the incidence and severity of late effects. We report our experience with 32 pediatric patients treated with proton RT...
  6. Novel molecular pathways in Gorham disease: implications for treatment.

    Pediatric Blood & Cancer 61(3):401 (2014) PMID 24214028 PMCID PMC4123459

    Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to collect. Gorham disease is a rare form of lymphatic proliferation accompa...
  7. Novel molecular pathways in Gorham disease: implications for treatment.

    Pediatric Blood & Cancer 61(3):401 (2014) PMID 24214028 PMCID PMC4123459

    Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to collect. Gorham disease is a rare form of lymphatic proliferation accompa...
  8. Novel molecular pathways in Gorham disease: implications for treatment.

    Pediatric Blood & Cancer 61(3):401 (2014) PMID 24214028 PMCID PMC4123459

    Rapid advances in evidence-based treatment schedules are a hallmark of modern oncology. In rare neoplastic diseases, however, clinical expertise is hard to build and evidence based on randomized trials almost impossible to collect. Gorham disease is a rare form of lymphatic proliferation accompa...
  9. Case records of the Massachusetts General Hospital. Case 27-2013. A 6.5-month-old boy with fever, rash, and cytopenias.

    New England Journal of Medicine 369(9):853 (2013) PMID 23984733

  10. Case records of the Massachusetts General Hospital. Case 27-2013. A 6.5-month-old boy with fever, rash, and cytopenias.

    New England Journal of Medicine 369(9):853 (2013) PMID 23984733

  11. Do Histologic Criteria Predict Biologic Behavior of Giant Cell Lesions?

    Journal of Oral and Maxillofacial Surgery 70(11):2573 (2012)

    Purpose To determine whether the clinical behavior of giant cell lesions (GCLs) or their anatomic location can be differentiated by histologic criteria alone.
  12. Do histologic criteria predict biologic behavior of giant cell lesions?

    Journal of Oral and Maxillofacial Surgery 70(11):2573 (2012) PMID 22365980

    To determine whether the clinical behavior of giant cell lesions (GCLs) or their anatomic location can be differentiated by histologic criteria alone. We performed a retrospective study of patients with GCLs treated at Massachusetts General Hospital between 1993 and 2008. Predictor variables wer...
  13. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

    Cancer 118(18):4597 (2012) PMID 22252521 PMCID PMC4008337

    There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. Patients with high-grade osteosarcoma of an...
  14. Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

    Cancer 118(18):4597 (2012) PMID 22252521 PMCID PMC4008337

    There are conflicting data regarding age as a prognostic factor in osteosarcoma. The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials. Patients with high-grade osteosarcoma of an...
  15. Proton radiotherapy for pediatric Ewing's sarcoma: initial clinical outcomes.

    International Journal of Radiation Oncology*Bio... 82(3):1142 (2012) PMID 21856094

    Proton radiotherapy (PT) has been prescribed similarly to photon radiotherapy to achieve comparable disease control rates at comparable doses. The chief advantage of protons in this setting is to reduce acute and late toxicities by decreasing the amount of normal tissue irradiated. We report the...
  16. Proton Radiotherapy for Pediatric Ewing’s Sarcoma: Initial Clinical Outcomes

    International Journal of Radiation Oncology*Bio... 82(3):1142 (2012)

    Purpose Proton radiotherapy (PT) has been prescribed similarly to photon radiotherapy to achieve comparable disease control rates at comparable doses. The chief advantage of protons in this setting is to reduce acute and late toxicities by decreasing the amount of normal tiss...
  17. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.

    Cancer 117(19):4522 (2011) PMID 21448934 PMCID PMC3716000

    A study was undertaken to assess clinical outcome and the role of proton therapy for local control of osteosarcoma (OSA). All patients who received proton therapy or mixed photon-proton radiotherapy from 1983 to 2009 at the Massachusetts General Hospital were reviewed. Criteria for proton therap...
  18. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma.

    Cancer 117(19):4522 (2011) PMID 21448934 PMCID PMC3716000

    A study was undertaken to assess clinical outcome and the role of proton therapy for local control of osteosarcoma (OSA). All patients who received proton therapy or mixed photon-proton radiotherapy from 1983 to 2009 at the Massachusetts General Hospital were reviewed. Criteria for proton therap...
  19. Case records of the Massachusetts General Hospital. Case 20-2007. An 11-year-old boy with a calcified mass in the nose.

    New England Journal of Medicine 356(26):2721 (2007) PMID 17596608

  20. Platelet-derived growth factor receptor-beta in Gorham's disease.

    Nature clinical practice. Oncology 3(12):693 (2006) PMID 17139320 PMCID PMC2693369

    A 17-year-old male presented with pain in his lower-left chest. He had no significant medical history and was previously in good health. He had a fractured ninth left anterior rib and the tenth, eleventh and twelfth ribs were absent, which was thought to be a congenital anomaly. Several months l...